Short Interest in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Declines By 57.9%

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) was the target of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 12,043 shares, a decrease of 57.9% from the June 15th total of 28,598 shares. Based on an average trading volume of 43,196 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the shares of the stock are short sold.

Oaktree Acquisition Corp. III Life Sciences Price Performance

Shares of OACC stock traded up $0.01 during mid-day trading on Wednesday, hitting $10.71. 5,525 shares of the company’s stock were exchanged, compared to its average volume of 37,777. Oaktree Acquisition Corp. III Life Sciences has a fifty-two week low of $10.30 and a fifty-two week high of $10.74. The stock has a 50-day simple moving average of $10.69 and a two-hundred day simple moving average of $10.66.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

Hedge funds have recently added to or reduced their stakes in the business. Empyrean Capital Partners LP grew its holdings in Oaktree Acquisition Corp. III Life Sciences by 20.0% in the 4th quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock valued at $9,522,000 after buying an additional 150,000 shares during the period. Lighthouse Investment Partners LLC boosted its position in shares of Oaktree Acquisition Corp. III Life Sciences by 88.9% in the second quarter. Lighthouse Investment Partners LLC now owns 850,000 shares of the company’s stock worth $8,882,000 after acquiring an additional 400,000 shares during the last quarter. Sculptor Capital LP grew its holdings in Oaktree Acquisition Corp. III Life Sciences by 6.1% in the fourth quarter. Sculptor Capital LP now owns 530,537 shares of the company’s stock valued at $5,613,000 after purchasing an additional 30,537 shares during the period. Goldman Sachs Group Inc. purchased a new stake in Oaktree Acquisition Corp. III Life Sciences in the first quarter valued at approximately $5,417,000. Finally, Moore Capital Management LP acquired a new position in Oaktree Acquisition Corp. III Life Sciences during the second quarter worth approximately $5,502,000.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Oaktree Acquisition Corp. III Life Sciences has a consensus rating of “Sell”.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.